StockNews.com began coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Free Report) in a research report released on Monday. The brokerage issued a buy rating on the biopharmaceutical company’s stock.
Acorda Therapeutics Stock Performance
The company has a 50 day moving average price of $10.27 and a 200-day moving average price of $11.87. Acorda Therapeutics has a 1 year low of $0.61 and a 1 year high of $24.20. The company has a market capitalization of $820,000.00, a P/E ratio of 0.00 and a beta of 1.40. The company has a quick ratio of 0.26, a current ratio of 0.33 and a debt-to-equity ratio of 3.07.
About Acorda Therapeutics
Recommended Stories
- Five stocks we like better than Acorda Therapeutics
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Roblox: The Bottom Just Fell Out of the Metaverse
- Election Stocks: How Elections Affect the Stock Market
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- How is Compound Interest Calculated?
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.